Event

Early-effective treatment: Case study discussion


10 May 2021 12:00 - 13:30

There is restricted access to the live webinars. Access to the live webinars is for health professionals working in MS services and a limited number of MS charity representatives and pharmaceutical representatives. If you are not granted access to the live webinar, you will be able to review the footage, which will be posted on our website shortly after the webinar has been conducted.

MS Academy will hold a live webinar on Monday, 10 May at 12.00 BST. The webinar will be reviewing contemporary therapeutic strategies in the management of MS, and will compare slow-escalation with rapid escalation and flipping the pyramid.

You are invited to watch the video conference from your computer, tablet or phone. The webinar will be live via Zoom for 1 hour 30 minutes and a recording will be available following the meeting.

12:00-12:45 - Early-effective treatment: Case study discussion
12:45-12:50 - Break
12:50-13:30 - Novartis Satellite Symposium
Prof Gavin Giovannoni

Professor of Neurology, Barts and The London School of Medicine and Dentistry

Prof Neil Robertson

Professor of Neurology, Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University

Rachel Dorsey-Campbell

Senior Lead Pharmacist, Neurosciences & NHSE Clinical Commissioning, Imperial College Healthcare NHS Trust

Case​:

A 44-year old male realises he may have SPMS. He has noted that his walking distance has deteriorated and after about 10 minutes his right leg starts to drag. A year ago he was able to manage 5 km without difficulty. He was diagnosed 5-years ago after presenting with myelitis and lower limb weakness and a previous episode of vertigo. His MRI has a high lesion load, posterior fossa and several spinal cord lesions. After failing glatiramer acetate due to a relapse he was switched to fingolimod. On researching the literature he asks his consultant why he was not offered alemtuzumab when he was diagnosed with MS 5-years ago?

"He asks if he can be switched to alemtuzumab or siponimod. What are you going to advise?"


This webinar has received sponsorship from Novartis Pharmaceuticals UK limited. The first session in the webinar is designed and delivered by the MS Academy and sponsored by Novartis Pharmaceuticals UK limited; the sponsor has had no input into the educational content or organisation of the session. The second session is a satellite symposium that is organised and funded by Novartis Pharmaceuticals UK limited.

Novartis Satellite Symposium:
When & how to switch eligible patients to MAYZENT▼ (siponimod) – Real World Experience

Prof Gavin Giovannoni

Professor of Neurology, Barts and The London School of Medicine and Dentistry

Prof Christoph Kleinschnitz

Director Clinic of Neurology, University Hospital Essen, Germany

Please join us to hear Prof Christoph Kleinschnitz share his experience in switching patients to MAYZENT. He will provide an overview of the current status of patients from his clinic including baseline characteristics as well as preliminary efficacy and safety data.

UK | April 2021 | 120556
Prescribing information for MAYZENT▼ (siponimod) and adverse event reporting details can be found here.


This event is free to attend as a result of sponsorship from our sponsors. The current event sponsors are listed on this page. In the interest of Neurology Academy and our sponsors’ legitimate business interests, we make available your name, job title and workplace to our sponsors. It allows us to attract the most appropriate sponsors, delegates and speakers for the events and to facilitate potential collaboration and communication between you and the sponsors; and allows us to offer other relevant events and services to the healthcare and life science industries. You can ask us not to share your your name, job title and workplace by emailing info@neurologyacademy.org. We respect the privacy of every person for whom we have personal data. The group privacy and cookies policy can be viewed here.

Book your place now
Our sponsor

This webinar has received sponsorship from Novartis Pharmaceuticals UK limited. The first session in the webinar is designed and delivered by the MS Academy and sponsored by Novartis Pharmaceuticals UK limited; the sponsor has had no input into the educational content or organisation of the session. The second session is a satellite symposium that is organised and funded by Novartis Pharmaceuticals UK limited.

Book your place now
Register now
Encouraging excellence, developing leaders, inspiring change

MS Academy was established six years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.